Microneedling vs Minoxidil vs Finasteride for Hair Loss
How does microneedling compare with minoxidil and finasteride for treating hair loss?
Most people line these three up like contenders in a bracket, and that's the mistake that costs them a year. Each one steps into the same disease at a different point, which is why the strongest evidence describes them stacked rather than picked. What you're actually choosing is the combination you'll still be doing in five years.
| Measure | Finasteride 1 mg | 5% Topical Minoxidil | Microneedling |
|---|---|---|---|
| Where it acts | Hormone conversion, systemic | Follicle, topical | Skin and stem cell niche, mechanical |
| Best evidence | 5 years, 1,553 men | 48 weeks, ~19 hairs per one inch area | 12 weeks, 100 men, with minoxidil |
| Main risk | Sexual side effects, 3.8% vs 2.1% placebo | Irritation, shedding, unwanted facial hair | Infection, pigment change, technique |
| Running cost | About 10 to 25 dollars a month | About 10 to 30 dollars a month | 30 to 80 dollars at home, hundreds per clinic session |
Finasteride lowers scalp dihydrotestosterone by 60 to 70 percent, minoxidil extends the follicle's growth phase without touching the hormone, and microneedling triggers a wound healing response while opening channels that let a topical drug penetrate far past the stratum corneum.
What mechanism does each of the three treatments use to influence hair growth?
Three completely different biological levers get pulled here, and knowing which is which explains almost everything about how each treatment behaves in practice. Two of them have a defined molecular target and a number you can measure. The third is a general regenerative response, which is both why it's appealing and why nobody can dose it precisely.
- Hormone conversion: Finasteride inhibits type II 5-alpha reductase, cutting scalp DHT 60 to 70 percent.
- Channel opening: Minoxidil sulfate hyperpolarises the dermal papilla, widens vessels and prolongs anagen.
- Controlled injury: Punctures of 0.5 to 1.5 mm release growth factors and activate Wnt signalling.
- Delivery window: Needling defeats the stratum corneum for hours, so topicals reach deeper.
Minoxidil only works once follicular sulfotransferase converts it into minoxidil sulfate, so a person with low scalp enzyme activity responds poorly no matter how faithfully they apply it.
How do the measured regrowth results compare across published clinical trials?
The dramatic numbers belong to needling and the durable numbers belong to the drugs, and almost all of that gap is study design rather than biology. A twelve week hair count and a five year outcome aren't the same currency, because short trials flatter anything that pushes follicles into growth all at once. If you see a figure quoted without its duration, its control arm and how it was measured, treat it as marketing.
| Measure | Needling plus minoxidil | Minoxidil alone | Finasteride 1 mg |
|---|---|---|---|
| Headline result | About 91 hairs per cm² | About 22 hairs per cm² | 93% less further visible loss than placebo |
| Duration | 12 weeks | 48 weeks | 5 years |
| Size | 100 men, single centre | Pivotal registration trials | 1,553 men |
| Weak spot | Unblindable, thinly replicated | Modest, mostly stabilising | Men only, hormonal exposure |
Forty eight week studies of 5 percent topical minoxidil report mean non-vellus hair count gains of about 19 hairs in a one inch target area, against about 13 hairs for the 2 percent strength.
What side effect profiles separate the three options?
When the efficacy differences look too close to call, risk is what decides it, and here the three stop resembling each other entirely. One trades a systemic hormonal exposure for the best characterised results; one causes mostly local trouble you can design around; one has no drug in it at all and is still a wound.
Finasteride 1 mg lowers prostate specific antigen, with mean values in the trials falling from 0.7 to 0.5 nanograms per millilitre over twelve months, so a screening result read without that context can look falsely reassuring.
How does each option differ in the long term commitment it demands?
None of these is a course of treatment with an end date, and pretending otherwise is the single most common reason people are disappointed two years in. The burdens differ in texture rather than in length, so the honest question is which routine you'll still keep when the novelty is gone.
Stop and the follicles resume the trajectory they were on, shedding the treatment-dependent hairs within three to four months for minoxidil and within twelve months for finasteride.
Which patients are good candidates for each treatment and who is ruled out?
Candidacy narrows fastest around finasteride and widens fastest around microneedling, and that asymmetry drives most real world prescribing. Work out which door is closed to you before you compare results, because a treatment you can't take has no success rate.
Finasteride is absolutely contraindicated in women who are pregnant or may become pregnant because of the risk of feminising a male foetus, and it has never been approved for women at any age.
What does combining microneedling with a drug achieve that either does alone?
Combination is where needling earns most of its clinical reputation, because it brings two things at once that a drug can't supply for itself: the signalling of a controlled wound, and a delivery route. Transient channels through the stratum corneum can lift a topical's penetration several-fold, so the same bottle of minoxidil reaches the dermal papilla in amounts it otherwise never would. That's exactly why the landmark trial tested needling with minoxidil rather than needling alone.
- Get the drug settled first: Run the topical or tablet for two to three months and confirm you tolerate it before adding anything.
- Needle on a skipped day: Do the session on a day you leave the topical off, so the drug isn't going into open channels.
- Wait about twenty four hours: Resume the topical once the channels have closed, and keep alcohol-based solutions, fragranced products and cosmetic serums off the scalp during that window.
- Photograph on a fixed schedule: Same lighting, same part line, same intervals, because a shed at week four and a plateau at month six could each belong to any component.
Because microneedling raises transdermal absorption several-fold, applying a topical to a freshly needled scalp increases both irritation and systemic exposure, so the common protocol skips the drug that day and resumes it roughly twenty four hours later.
How do the yearly costs of the three approaches compare?
On a straight annual basis the two drugs are the cheap end and needling is the line item that swings wildly depending on who holds the device. Spend your money on the version you'll sustain, because the density lost during a year off treatment generally doesn't come back when you restart.
Both drugs together run roughly 300 to 600 dollars a year at prevailing prices, while a first year of in-clinic needling commonly reaches 1,500 to 3,000 dollars, and almost none of it is reimbursed because androgenetic alopecia is classified as cosmetic.
Which regulatory approvals stand behind each treatment?
Only two of the three have ever been through an approval for hair loss, and knowing which is which reframes a lot of the language you'll see in advertising. Off label and uncleared don't mean unproven or forbidden, but they do mean nobody reviewed a safety and efficacy dossier for that specific use.
- Topical minoxidil: Approved for men in the 1980s, later for women, sold over the counter.
- Oral finasteride 1 mg: Approved in 1997 for men; any use in women is off label.
- Microneedling devices: Cleared for acne scars and wrinkles, never for androgenetic alopecia.
- Consumer rollers: Often not regulated as medical devices, so needle quality varies widely.
No microneedling device in mainstream markets holds an indication for androgenetic alopecia, so any advertisement calling a device approved for hair loss is misstating its status.
How does the stage and pattern of loss change which option is chosen?
Stage is the variable that quietly decides whether any of this works, and it gets assessed before you choose a product, not after a year of disappointment. Location matters nearly as much: the vertex and mid-scalp respond considerably better to both drugs and needling than the frontal hairline and temporal recession.
The hair cycle fixes the timeline regardless of which option you pick: nothing meaningful can be judged before three months, six months is the first fair assessment, and twelve months is where the true ceiling shows.
